Mirati Therapeutics (MRTX) Misses Q4 EPS by 76c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mirati Therapeutics (MRTX) PT Lowered to $125 at Oppenheimer
March 1, 2022 3:54 PM ESTOppenheimer analyst Jay Olson lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $125.00 (from $155.00) while maintaining a Perform rating.
The analyst commented, "MRTX reported 4Q21 R&D expenses of $153.8M and G&A expenses of $43.5M, driving a net loss of... More
Mirati Therapeutics (MRTX) PT Lowered to $118 at Stifel
March 1, 2022 6:26 AM ESTStifel analyst Ben Burnett lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $118.00 (from $150.00) while maintaining a Buy rating.
The analyst commented, "We remain Buy rated on MRTX shares following the company's 2Q22 update; we continue to believe that CNS data will differentiate... More
